Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The outlook on the prevention, diagnosis and treatment of Alzheimer’s disease is brighter than ever. Backed by decades of research, the field is beginning to see tangible success in moving basic biological insights into actual diagnostics and therapeutics.
Early studies suggest that lifestyle changes such as diet, exercise and social engagement may help slow or prevent Alzheimer’s symptoms—but the evidence is inconsistent, and many doctors remain cautious.
While our understanding of Alzheimer’s disease is far from complete, the latest therapies, and others in more than 100 clinical trials, offer new hope.
New Alzheimer’s drugs known as anti-amyloid therapies may slow disease progression—but they also carry serious risks, including brain bleeds and strokelike symptoms.
A new generation of Alzheimer’s blood tests could speed up diagnosis and access to care—but they also raise thorny questions about prediction, treatment and uncertainty.
More than 13.8 million Americans could have Alzheimer’s by 2060, and at the rate care facilities are closing, many of them will have nowhere to go. Regina Shih of the State Alzheimer’s Research Support Center (StARS) wants to help solve that problem.
Black Americans face a significantly higher risk of Alzheimer’s and other dementias than white Americans. Researchers are working to find out why that is and how to intervene.
“Smoldering” describes a group of processes that drive chronic disease progression, and introduces a fresh perspective to the complex interplay of Alzheimer’s disease pathology.